- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
I like Paysign, Inc. (PAYS)
Posted on 3/26/26 at 11:23 am
Posted on 3/26/26 at 11:23 am
I found this on a scanner AFTER the huge move on earnings 
But I think it will still be a great investment. This one is not as speculative as others I've mentioned. It's more of a fundamental investment.
I was looking for small market cap, profitability, growth, but also trading at an attractive valuation. I'm very happy to have found Paysign.
Here's some AI driven content that I've steered:
Paysign provides specialized fintech solutions for pharmaceutical copay assistance and plasma donor compensation through its proprietary payment processing platform.
As of late March 2026, Paysign has reached a milestone where its high-margin pharmaceutical payment services are beginning to equal its legacy plasma business in total revenue. This shift follows a year of expansion in which the company added 55 new patient affordability programs and completed a strategic acquisition to deepen its integration into plasma collection centers. With a debt-free balance sheet and a focus on technology that reduces costs for pharmaceutical manufacturers, the company is now prioritizing profitability through operating leverage.
1. Hyper-Growth Pharma Pivot: Paysign is transforming into a high-margin pharmaceutical fintech, with pharma revenue growing 168% in 2025.
2. Powerful Operating Leverage: Management expects to nearly double net income to a 14.5 million dollar midpoint in 2026 on 32% revenue growth.
3. Attractive Valuation: Trading at a 0.44 PEG ratio and roughly 22x forward earnings, the stock remains undervalued relative to its 90% income growth.
4. Clean Balance Sheet: The company is entirely debt-free with 21.1 million dollars in unrestricted cash, allowing it to self-fund all current expansion.
5. Bullish Analyst Outlook: Wall Street maintains a 9.25 dollar consensus price target, implying roughly 80% upside from current trading levels.
A bit on Dynamic Business Rules:
The Dynamic Business Rules (DBR) technology effectively acts as a referee in a high-stakes financial game. Here is how the power dynamics shift when Paysign is in the middle:
The Winners
Drug Makers (Pharma): They are the biggest winners. They stop "bleeding" money to insurance middlemen. In 2025 alone, they kept $325 million that would have otherwise been siphoned away. This allows them to maintain their assistance budgets and help more people.
Patients: They win through stability. Instead of their copay assistance "running out" in April because an insurer drained the fund, Paysign’s metering ensures the money lasts all 12 months. This prevents "cost shock" and helps patients stay on their life-saving meds.
Paysign (PAYS): By proving they can save a Top-10 pharma company millions of dollars on day one, Paysign becomes "un-fireable." This tech is their primary "moat" that is currently driving their 90% income growth.
The Losers
Insurance Companies & PBMs: They are the clear losers. For years, they used "Maximizer" and "Accumulator" programs to quietly pocket manufacturer assistance funds for themselves. Paysign’s 97% accuracy in spotting these tricks effectively shuts down a major, hidden revenue stream for insurers.
But I think it will still be a great investment. This one is not as speculative as others I've mentioned. It's more of a fundamental investment.
I was looking for small market cap, profitability, growth, but also trading at an attractive valuation. I'm very happy to have found Paysign.
Here's some AI driven content that I've steered:
Paysign provides specialized fintech solutions for pharmaceutical copay assistance and plasma donor compensation through its proprietary payment processing platform.
As of late March 2026, Paysign has reached a milestone where its high-margin pharmaceutical payment services are beginning to equal its legacy plasma business in total revenue. This shift follows a year of expansion in which the company added 55 new patient affordability programs and completed a strategic acquisition to deepen its integration into plasma collection centers. With a debt-free balance sheet and a focus on technology that reduces costs for pharmaceutical manufacturers, the company is now prioritizing profitability through operating leverage.
1. Hyper-Growth Pharma Pivot: Paysign is transforming into a high-margin pharmaceutical fintech, with pharma revenue growing 168% in 2025.
2. Powerful Operating Leverage: Management expects to nearly double net income to a 14.5 million dollar midpoint in 2026 on 32% revenue growth.
3. Attractive Valuation: Trading at a 0.44 PEG ratio and roughly 22x forward earnings, the stock remains undervalued relative to its 90% income growth.
4. Clean Balance Sheet: The company is entirely debt-free with 21.1 million dollars in unrestricted cash, allowing it to self-fund all current expansion.
5. Bullish Analyst Outlook: Wall Street maintains a 9.25 dollar consensus price target, implying roughly 80% upside from current trading levels.
A bit on Dynamic Business Rules:
The Dynamic Business Rules (DBR) technology effectively acts as a referee in a high-stakes financial game. Here is how the power dynamics shift when Paysign is in the middle:
The Winners
Drug Makers (Pharma): They are the biggest winners. They stop "bleeding" money to insurance middlemen. In 2025 alone, they kept $325 million that would have otherwise been siphoned away. This allows them to maintain their assistance budgets and help more people.
Patients: They win through stability. Instead of their copay assistance "running out" in April because an insurer drained the fund, Paysign’s metering ensures the money lasts all 12 months. This prevents "cost shock" and helps patients stay on their life-saving meds.
Paysign (PAYS): By proving they can save a Top-10 pharma company millions of dollars on day one, Paysign becomes "un-fireable." This tech is their primary "moat" that is currently driving their 90% income growth.
The Losers
Insurance Companies & PBMs: They are the clear losers. For years, they used "Maximizer" and "Accumulator" programs to quietly pocket manufacturer assistance funds for themselves. Paysign’s 97% accuracy in spotting these tricks effectively shuts down a major, hidden revenue stream for insurers.
2
Posted on 3/26/26 at 2:51 pm to bayoubengals88
Look for the legacy, lower margin, Plasma segment of the business to get an upgrade from the FDA in the next couple of months.
This would transform the company into 100% software based with higher overall margins and opportunities for growth.
Regulatory Tailwinds
Interestingly, the FDA recently updated its guidance in January 2026 regarding "Clinical Decision Support" software. The new guidelines favor software that is transparent and supports healthcare professionals rather than replacing them. Paysign’s BECS is designed exactly to this standard, which may explain management’s high confidence in the 60-day approval window.
Summary for an Investor:
If the FDA clears this software in May 2026, Paysign stops being a "card company" and officially becomes a Regulated Healthcare Software Company.
This typically leads to a much higher valuation multiple (P/E ratio) from Wall Street.
This would transform the company into 100% software based with higher overall margins and opportunities for growth.
Regulatory Tailwinds
Interestingly, the FDA recently updated its guidance in January 2026 regarding "Clinical Decision Support" software. The new guidelines favor software that is transparent and supports healthcare professionals rather than replacing them. Paysign’s BECS is designed exactly to this standard, which may explain management’s high confidence in the 60-day approval window.
Summary for an Investor:
If the FDA clears this software in May 2026, Paysign stops being a "card company" and officially becomes a Regulated Healthcare Software Company.
This typically leads to a much higher valuation multiple (P/E ratio) from Wall Street.
Posted on 3/26/26 at 4:35 pm to bayoubengals88
you are late.
i am up 82% on this. bought quite some time back.
i am up 82% on this. bought quite some time back.
Posted on 3/26/26 at 4:53 pm to Fat Bastard
Thanks for the help!!
While I wish I had discovered this one just 24 hrs earlier, the earnings report made it even easier to buy.
This is not a stock you will ever see on CNBC, but I think it has a great shot at become 3-4x bigger than it is now.
Probably a great acquisition candidate too.
You got anything else to add?!
While I wish I had discovered this one just 24 hrs earlier, the earnings report made it even easier to buy.
This is not a stock you will ever see on CNBC, but I think it has a great shot at become 3-4x bigger than it is now.
Probably a great acquisition candidate too.
You got anything else to add?!
Posted on 3/26/26 at 6:10 pm to bayoubengals88
follow this guy. he gave me this stock tip way back.
you're welcome
you're welcome
Posted on 3/27/26 at 10:34 am to Fat Bastard
Quietly up 5% on this terrible market day.
I bought more this morning
I bought more this morning
This post was edited on 3/27/26 at 10:36 am
Posted on 3/30/26 at 9:18 am to bayoubengals88
PAYS has moved from $5 to $6 over the course of four of the worst market days we've seen in a long time.
I think there's still about 66% upside from here.
I think there's still about 66% upside from here.
Posted on 4/9/26 at 3:13 pm to bayoubengals88
Update:
* PaySign officially updated its 2026 financial guidance today, projecting total revenue between 106.5 million and 110.5 million dollars. This targets an annual growth rate of 30 to 35 percent, which is significantly higher than earlier market estimates.
* The company expects its full-year net income to land between 13 million and 16 million dollars. This would result in earnings per share of 21 to 26 cents, nearly doubling the profitability seen in the previous year.
* Growth is being spearheaded by the pharmaceutical patient affordability segment. The company expects to have 137 active programs by the end of this quarter and has already secured partnerships with six of the top ten global pharmaceutical manufacturers.
* For the first quarter of 2026 specifically, management is guiding for revenue of 27 million to 27.5 million dollars. This would represent a 45 percent increase compared to the same period last year, highlighting the rapid pace of their current expansion.
* Despite the morning's price volatility, major analysts maintain bullish ratings on the stock. Price targets from firms like Lake Street and DA Davidson remain high, ranging from 9.00 to 11.00 dollars, based on the company’s expanding profit margins.
* PaySign officially updated its 2026 financial guidance today, projecting total revenue between 106.5 million and 110.5 million dollars. This targets an annual growth rate of 30 to 35 percent, which is significantly higher than earlier market estimates.
* The company expects its full-year net income to land between 13 million and 16 million dollars. This would result in earnings per share of 21 to 26 cents, nearly doubling the profitability seen in the previous year.
* Growth is being spearheaded by the pharmaceutical patient affordability segment. The company expects to have 137 active programs by the end of this quarter and has already secured partnerships with six of the top ten global pharmaceutical manufacturers.
* For the first quarter of 2026 specifically, management is guiding for revenue of 27 million to 27.5 million dollars. This would represent a 45 percent increase compared to the same period last year, highlighting the rapid pace of their current expansion.
* Despite the morning's price volatility, major analysts maintain bullish ratings on the stock. Price targets from firms like Lake Street and DA Davidson remain high, ranging from 9.00 to 11.00 dollars, based on the company’s expanding profit margins.
This post was edited on 4/9/26 at 3:20 pm
Posted on 4/14/26 at 9:02 pm to bayoubengals88
PAYS hasn't really done anything since the 3/25 pop. Sad.
(Secretly, I'm crapping on the stock because when I do, stocks usually prove me wrong in a big way)
(Secretly, I'm crapping on the stock because when I do, stocks usually prove me wrong in a big way)
Posted on 4/14/26 at 9:23 pm to bayoubengals88
just checked. i am up 94% now.
Posted on 4/17/26 at 12:11 pm to TDFreak
quote:Well done!
PAYS hasn't really done anything since the 3/25 pop. Sad.
(Secretly, I'm crapping on the stock because when I do, stocks usually prove me wrong in a big way)
Page 1 of 1
Popular
Back to top
Follow TigerDroppings for LSU Football News